These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

947 related articles for article (PubMed ID: 14585769)

  • 1. Evaluating medication effects outside of clinical trials: new-user designs.
    Ray WA
    Am J Epidemiol; 2003 Nov; 158(9):915-20. PubMed ID: 14585769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them.
    Fu EL; van Diepen M; Xu Y; Trevisan M; Dekker FW; Zoccali C; Jager K; Carrero JJ
    Clin Kidney J; 2021 May; 14(5):1317-1326. PubMed ID: 33959262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.
    Suissa S; Moodie EE; Dell'Aniello S
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):459-468. PubMed ID: 27610604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.
    Lancet; 1997 Oct; 350(9084):1047-59. PubMed ID: 10213546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.
    Acton EK; Willis AW; Hennessy S
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):9-18. PubMed ID: 36216785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incident user design in comparative effectiveness research.
    Johnson ES; Bartman BA; Briesacher BA; Fleming NS; Gerhard T; Kornegay CJ; Nourjah P; Sauer B; Schumock GT; Sedrakyan A; Stürmer T; West SL; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):1-6. PubMed ID: 23023988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.
    Col NF; Hirota LK; Orr RK; Erban JK; Wong JB; Lau J
    J Clin Oncol; 2001 Apr; 19(8):2357-63. PubMed ID: 11304788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited Commentary: The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities.
    Filion KB; Yu YH
    Am J Epidemiol; 2021 Jul; 190(7):1349-1352. PubMed ID: 33350439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience?
    Col NF; Pauker SG
    Ann Intern Med; 2003 Dec; 139(11):923-9. PubMed ID: 14644895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence from randomised trials on the long-term effects of hormone replacement therapy.
    Beral V; Banks E; Reeves G
    Lancet; 2002 Sep; 360(9337):942-4. PubMed ID: 12354487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 3. The Women's Health Initiative: unopposed estrogen.
    Shapiro S; Farmer RD; Mueck AO; Seaman H; Stevenson JC
    J Fam Plann Reprod Health Care; 2011 Oct; 37(4):225-30. PubMed ID: 21642263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More realistic power estimation for new user, active comparator studies: an empirical example.
    Gokhale M; Buse JB; Pate V; Marquis MA; Stürmer T
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):462-6. PubMed ID: 26360635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential dietary nutrient intake according to hormone replacement therapy use: an underestimated confounding factor in epidemiologic studies?
    Vercambre MN; Fournier A; Boutron-Ruault MC; Clavel-Chapelon F; Ringa V; Berr C
    Am J Epidemiol; 2007 Dec; 166(12):1451-60. PubMed ID: 17698505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiator Types and the Causal Question of the Prevalent New-User Design: A Simulation Study.
    Webster-Clark M; Ross RK; Lund JL
    Am J Epidemiol; 2021 Jul; 190(7):1341-1348. PubMed ID: 33350433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature.
    Bromley SE; de Vries CS; Thomas D; Farmer RD
    Drug Saf; 2005; 28(6):473-93. PubMed ID: 15924502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of coronary heart disease in determining use of hormone replacement therapy in a general practice population.
    Chin BS; Futaba K; Jethwa A; Lip GY
    Int J Clin Pract; 2001 Oct; 55(8):515-8. PubMed ID: 11695070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and the risk of melanoma in post-menopausal women.
    Hicks BM; Kristensen KB; Pedersen SA; Hölmich LR; Pottegård A
    Hum Reprod; 2019 Dec; 34(12):2418-2429. PubMed ID: 31803923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of hormone replacement therapy and coronary calcium as determined by electron beam tomography.
    Schisterman EF; Gallagher AM; Bairey Merz CN; Whitcomb BW; Faraggi D; Moysich KB; Lewin H
    J Womens Health Gend Based Med; 2002 Sep; 11(7):631-8. PubMed ID: 12396895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.